Collaborating globally

We collaborate at a global level to increase understanding of fast-emerging and existing health threats in the developing world, and to lend our skills and resources to addressing these.

This includes participating in multi-stakeholder discussions centred on identifying pragmatic, collaborative approaches to overcoming the barriers to healthcare. And, alongside our in-house research, we partner with others in the search for new and effective medicines for developing world disease.

Tuberculosis and malaria

 Alongside the rising challenge of NCDs, the battle against tuberculosis (TB) is far from over. TB still claims over 1.4 million lives a year and remains one of the leading causes of death from infectious disease in the developing world.

AZD5847 is our most advanced potential new TB medicines, currently progressing in Phase 2 clinical trials. The focus is on finding a new therapy or combination of therapies that are effective against multi-drug resistant TB, that offer a shorter treatment regime and which are compatible with HIV/AIDs therapies (TB and HIV/AIDs form a lethal combination – each speeding the other’s progress). Read more

 In this complex area of research, however, no single company or treatment can meet the challenge alone. As well as our in-house efforts, we make our compound library available to researchers and also work alongside other organisations in multi-stakeholder partnerships, combining research skills and capabilities to help accelerate the development of new TB drugs.

Neglected tropical diseases

We have also recently been exploring ways in which we can help in the area of neglected tropical diseases (NTDs). NTDs (so called because of the lack of investment in the past) affect more than one billion people, primarily poor populations in tropical and sub-tropical areas. At the beginning of 2012, AstraZeneca, along with other pharmaceutical companies, the Bill & Melinda Gates Foundation (BMGF), the US and UK governments, the World Bank and officials from endemic countries announced a new, coordinated push to eliminate, or control, 10 NTDs by the end of the decade. This partnership will help provide the necessary drugs to combat NTDs, accelerate new research and development, sharing of intellectual property and manufacturing capabilities, and funding and support treatment implementation programmes.

We have also made significant contributions to the World Intellectual Property Organization’s WIPO Re:Search initiative. This is an unprecedented collaboration between the private and public sector designed to encourage new research partnerships and accelerate the discovery and development of new NTD treatments. WIPO Re:Search makes public an online searchable catalogue of available IP assets and resources for use in NTD research.

We have made all AstraZeneca’s published patents and patent applications available for licence, including royalty-free licences for NTD R&D in any country (subject only to pre-existing obligations to third parties).

Woman giving young girl something to eat

AstraZeneca is included in the IFPMA’s 2012 Developing World Health Partnerships Directory of contributions that research-based pharmaceutical companies make in the developing world.

Go back to...

Next section

Access to healthcare

Our access to healthcare strategy takes account of the different barriers to healthcare in different parts of the world.

Read more

Research ethics

Our commitment to high ethical standards of research and development applies across all aspects of our research activity worldwide.

Read more